In recent decades, molecular targeted therapy has demonstrated clinical efficacy in cancer patients, such as epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) for advanced NSCLC patients with EGFR mutations. Here, EGFR is linked to non-small cell lung carcinoma.